Servier CDMO offers a variety of tableting and encapsulation options to optimize your product’s therapeutic performance. Our tablet capabilities range from immediate, controlled and modified release to film and sugar coating, and we have the equipment and expertise to encapsulate powders, granules and micro-tablets.
Servier CDMO has high-performance production capabilities for a full range of dosage forms and product groups, including liquids, sprays and powders. Our manufacturing and packaging suites have separate air handling and filtration systems to ensure full quality control and assurance across the lifecycle of your product.
Servier CDMO provides custom manufacturing of APIs and HPAPIs from worldwide facilities. Our industry-leading methodologies, combined with state-of-the-art containment tools, enables us to handle your project from development through commercial phases, addressing any technical and regulatory challenges that may arise.
We manufacture pharmaceutical intermediates from state-of-the-art cGMP and FDA-approved chemical facilities around the world. Leveraging our integrated network of R&D, production and supply chain expertise, we provide intermediate manufacturing for both GMP and non-GMP requirements, from kilogram scale to several metric tons.
At Servier CDMO, we provide a number of cost-effective primary and secondary packaging options, including blisters, sachets and bottles. We strictly adhere to global standards for serialization and aggregation, and provide tamper-evident packaging and labeling in line with EU requirements.
Servier Egypt manufactures, packages and distributes over 540 million units of drug product annually from two integrated facilities in Cairo – our manufacturing site in Acacias and packaging center in Palmiers. Both operations hold ISO 9001, ISO 14001 and OHSAS 18001 accreditations, and are currently preparing for ISO 50001.
Servier’s Oril Industrie facility in Bolbec specializes in the development and manufacture of intermediates, APIs and HPAPIs for worldwide distribution.
Regulatory affairs activities are essential components of any drug development and commercialization program. CDMOs with extensive experience with product approvals that have regulatory affairs deeply integrated with other operational teams can provide optimized regulatory strategies.
Servier Group is proud to announce that it will develop its presence in the US market through the oncology therapeutic area. Servier CDMO, in accordance with the group’s strategy, continues to develop its services for High Potent drugs in API and drug product.